• Home
  • Formulary
    • Chapter Summaries
    • 1.0 Gastro intestinal System
      • 1.1 Dyspepsia and gastro-oesophageal reflux disease (GORD)
        • 1.1.1 Antacids and simeticone
        • 1.1.2 Compound alginates and proprietary indigestion preparations
      • 1.2 Antispasmodics and other drugs altering gut motility
      • 1.3 Antisecretory drugs and mucosal protectants
        • 1.3.1 H2-receptor antagonists
        • 1.3.5 Proton pump inhibitors
          • 1.3.5.1 H.pylori eradication
      • 1.4 Acute diarrhoea
      • 1.5 Chronic bowel disorders
        • 1.5.1 Aminosalicylates
          • 1.5.1.1 Acute Exacerbation of ulcerative colitis
          • 1.5.1.2 Maintenance of remission of ulcerative colitis
        • 1.5.2 Corticosteroids inflammatory bowel disease
        • 1.5.3 Steroid-sparing treatment for inflammatory bowel disease
      • 1.6 Laxatives
      • 1.7 Local preparations for anal and rectal disorders
        • 1.7.1 Soothing haemorrhoidal preparations
        • 1.7.2 Compound haemorrhoidal preparations with corticosteroids
        • 1.7.4 Management of anal fissures
      • 1.9 Drugs affecting intestinal secretions
        • 1.9.4 Pancreatic Exocrine Insufficiency
    • 2.0 Cardiovascular System
      • 2.1 Positive inotropic drugs
        • 2.1.1 Cardiac glycosides
      • 2.2 Diuretics
        • 2.2.1 Thiazides and related diuretics
        • 2.2.2 Loop diuretics
        • 2.2.3 Potassium-sparing diuretics and aldosterone antagonists
        • 2.2.4 Potassium-sparing diuretics with other diuretics
      • 2.3 Anti-arrhythmic drugs
        • 2.3.2 Drugs for arrhythmias
      • 2.4 Beta-adrenoceptor blocking drugs
      • 2.5 Hypertension and heart failure
        • 2.5.2 Centrally acting antihypertensive drugs
        • 2.5.4 Alpha-adrenoceptor blocking drugs
        • 2.5.5 Drugs affecting the renin-angiotensin system
          • 2.5.5.1 Angiotensin-converting enzyme inhibitors
          • 2.5.5.2 Angiotensin-II receptor antagonists (AIIRAs/ARBs)
          • 2.5.5.3 Renin inhibitors
      • 2.6 Nitrates, calcium-channel blockers and other antianginal drugs
        • 2.6.1 Nitrates
        • 2.6.2 Calcium-channel blockers (CCBs)
        • 2.6.3 Other antianginal drugs
        • 2.6.4 Peripheral vasodilators and related drugs
        • Review copy of – 2.6.3 Other antianginal drugs
      • 2.7 Sympathomimetics
      • 2.8 Anticoagulants and protamine
        • 2.8.1 Parenteral anticoagulants
        • 2.8.2 Oral anticoagulants
          • 2.8.2.1 Atrial fibrillation
          • 2.8.2.2 Treatment of pulmonary embolism and deep vein thrombosis and prevention of recurrent
          • 2.8.2.3 Prophylaxis of venous thromboembolism in orthopaedics-specialist use in secondary care only
          • 2.8.2.4 Acute coronary syndrome
          • 2.8.2.5 Prevention of Atherothrombotic events
      • 2.9 Antiplatelet drugs
      • 2.10 Stable angina, acute coronary syndromes and fibrinolysis
      • 2.11 Antifibrinolytic drugs and haemostatics
      • 2.12 Lipid-regulating drugs
    • 3.0 Respiratory System
      • 3.1 Bronchodilators
        • 3.1.1 Adrenoceptor agonists
        • 3.1.2 Antimuscarinic bronchodilators
        • 3.1.3 Theophylline
        • 3.1.4 Compound bronchodilator preparations
        • 3.1.5 Peak flow meters, inhaler devices and nebulisers
      • 3.2 Corticosteroids
        • 3.2.1 Single agent inhalers [asthma only]
        • 3.2.2 Compound ICS/LABA preparations – [asthma]
        • 3.2.3 Compound ICS/LABA preparations – COPD
        • 3.2.4 Systemic steroids
      • 3.3 Leukotriene receptor antagonists and phosphodiesterase type-4 inhibitors
        • 3.3.2 Leukotriene receptor antagonists
        • 3.3.3 Phosphodiesterase type-4 inhibitors
      • 3.4 Antihistamines, hyposensitisation and allergic emergencies
        • 3.4.1 Antihistamines
        • 3.4.2 Allergen immunotherapy (desensitisation)
        • 3.4.3 Allergic emergencies
      • 3.6 Oxygen
      • 3.7 Mucolytics
      • 3.9 Cough preparations
        • 3.9.1 Cough suppressants
    • 4.0 Central Nervous System
      • 4.1 Hypnotics and anxiolytics
        • 4.1.1 Hypnotics
        • 4.1.2 Anxiolytics
          • 4.1.2.1 Acute anxiety state
          • 4.1.2.2 Anxiety disorders
        • 4.1.3 Barbiturates
      • 4.2 Drugs used in psychoses and related disorders
        • 4.2.1 Antipsychotic drugs
          • 4.2.1.1 Management of agitation and aggression
        • 4.2.3 Mood stabilising drugs
          • 4.2.3.1 Treatment of the acute phase of mania
          • 4.2.3.2 Maintenance treatment of bipolar disorder with mood stabilisers
      • 4.3 Antidepressant drugs
        • 4.3.1 Mild, moderate and severe depression
        • 4.3.2 Antidepressants for the treatment of anxiety disorders*
          • 4.3.2.1 Generalised anxiety disorder (GAD), social anxiety disorder
          • 4.3.2.2 Panic disorder
          • 4.3.2.3 Post-traumatic stress disorder
          • 4.3.2.4 Obsessive compulsive disorder
      • 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder
        • 4.4.1 Narcolepsy
        • 4.4.2 Attention deficit hyperactive disorder (ADHD) in adults
      • 4.5 Drugs used in the treatment of obesity
        • 4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract
      • 4.6 Drugs used in nausea and vertigo
        • 4.6.1 Drugs for the short-term treatment of nausea and vomiting
          • 4.6.1.1 Motion sickness
        • 4.6.2 Vertigo
      • 4.7 Analgesics
        • 4.7.1 General management of acute pain
          • 4.7.1.1 Non-opioid & compound analgesics
          • 4.7.1.2 Opioid analgesics
        • 4.7.3 Neuropathic pain
        • 4.7.4 Antimigraine drugs
          • 4.7.4.1 Treatment of acute migraine attack
          • 4.7.4.2 Migraine prophylaxis
          • 4.7.4.3 Drug treatment of cluster headache
      • 4.8 Anti-epileptics
        • 4.8.1 Control of epilepsy
        • 4.8.2 Drugs used in status epilepticus
      • 4.9 Drugs used in parkinsonism and related disorders
        • 4.9.1 Dopaminergic drugs used in parkinsonism
          • 4.9.1.1 Dopamine receptor agonists
          • 4.9.1.2 Levodopa
          • 4.9.1.3 Monoamine-oxidase-B (MAOB) inhibitors
          • 4.9.1.4 Dopamine enzyme inhibitors / catechol-O-methyltransferase inhibitors (COMT inhibitors)
        • 4.9.2 Antimuscarinic drugs used in parkinsonism
        • 4.9.3 Essential tremor
        • 4.9.4 Management of dementia in Parkinson’s disease
      • 4.10 Medications used in substance use disorders
        • 4.10.1 Opioid maintenance prescribing
        • 4.10.2 Opioid detoxification
        • 4.10.3 Benzodiazepines addiction and withdrawal
        • 4.10.4 Alcohol dependence
          • 4.10.4.1 Acute alcohol withdrawal
          • 4.10.4.2 Relapse Prevention
          • 4.10.4.3 Interventions for the reduction of alcohol consumption
          • 4.10.4.4 Vitamin supplementation
        • 4.10.5 Cigarette smoking
      • 4.11 Drugs for dementia
        • 4.11.1 Management of Behavioural and Psychological Symptoms of Dementia (BPSD)
    • 5.0 Infections (including children)
    • 6.0 Endocrine
      • 6.1 Drugs used in diabetes
        • 6.1.1 Insulins
        • 6.1.2 Antidiabetic drugs
          • 6.1.2.1 Biguanides
          • 6.1.2.2 Sulfonlyureas
          • 6.1.2.3 Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors)
          • 6.1.2.4 Glitazones (thiazolidinediones)
          • 6.1.2.5 Sodium-glucose co-transporter 2 (SGLT-2) inhibitors
          • 6.1.2.6 GLP-1 mimetic (injectable)
          • Sick Day rules
        • 6.1.4 Treatment of hypoglycaemia
        • 6.1.6 Diagnostic and monitoring agents for diabetes mellitus
        • Summary of oral drug treatments for type 2 diabetes
      • 6.2 Thyroid and antithyroid drugs and parathyroid disease
        • 6.2.1 Hypothyroidism
        • 6.2.2 Hyperthyroidism
          • 6.2.2.1 Antithyroid drugs
          • 6.2.2.2 Beta-blockers
        • 6.2.3 Parathyroid disease
          • 6.2.3.1 Hyperparathyroidism
          • 6.2.3.2 Hypoparathyroidism
      • 6.3 Corticosteroids
        • 6.3.1 Replacement therapy
        • 6.3.2 Glucocorticoid therapy
      • 6.4 Sex hormones
        • 6.4.1.1 Hormone replacement therapy (HRT) for menopausal symptoms
          • 6.4.1.1a Women who have not had a hysterectomy
          • 6.4.1.1b Women who have had a hysterectomy or who have a Mirena® Intra Uterine System (ISU) in situ
        • 6.4.2 Male sex hormones
      • 6.5 Pituitary hormones and anti-oestrogens
        • 6.5.2 Posterior pituitary hormones and antagonists
          • 6.5.2.1 Diabetes insipidus
          • 6.5.2.2 Antidiuretic hormone antagonists
      • 6.6 Drugs affecting bone metabolism
        • 6.6.1 Drugs for the treatment and management of osteoporosis
          • 6.6.1.1 Calcium and vitamin D
          • 6.6.1.2 Bisphosphonates
          • 6.6.1.3 Other drug therapies used in osteoporosis
      • 6.7 Other endocrine drugs
        • 6.7.1 Dopamine-receptor agonists
        • 6.7.4 Growth hormone disorders
    • 7.0 Contraception, Gynaecology and Urinary Tract Disorders
      • 7.1.1 Primary dysmenorrhoea
      • 7.1.2 Heavy menstrual bleeding
      • 7.1.3 Endometriosis (previously diagnosed by laparoscopy)
      • 7.1.4 Lichen sclerosus
      • 7.1.5 Persistent breast pain
      • 7.1.6 Premenstrual tension syndrome
      • 7.1.7 Polycystic ovarian syndrome
      • 7.2 Treatment of vaginal and vulval conditions
        • 7.2.1 Preparations for vaginal and vulval changes
        • 7.2.2 Vaginal and vulval infections
      • 7.3 Contraceptives
        • 7.3.1 Combined hormonal oral contraceptives
        • 7.3.2 Progestogen-only contraceptives
          • 7.3.2.1 Oral progestogen-only contraceptives
          • 7.3.2.2 Parenteral progestogen-only contraceptives
          • 7.3.2.3. Intra-uterine progestogen-only device
        • 7.3.4 Contraceptive devices
        • 7.3.5 Emergency contraception
        • 7.3.6 Delaying Menstruation During Holidays
      • 7.4 Drugs for genito-urinary disorders
        • 7.4.1 Drugs for voiding (obstructive) symptoms in men
        • 7.4.2 Drugs for urinary frequency, enuresis, and incontinence
        • 7.4.3 Drugs used in urological pain
        • 7.4.5 Drugs for erectile dysfunction
    • 8.0 Malignant Disease and Immunosuppression
    • 9.0 Nutrition and Blood
      • 9.1 Anaemias and some other blood disorders
        • 9.1.1 Iron deficiency anaemia
          • 9.1.1.1 Oral iron
        • 9.1.2 Drugs used in megaloblastic anaemias
      • 9.4 Oral Nutrition
      • 9.5 Minerals
        • 9.5.1.1 Calcium supplement
      • 9.6 Vitamins
        • 9.6.2 Vitamin B group
        • 9.6.4 Vitamin D
        • 9.6.7 Multivitamins
      • Infant Feeding
      • Supplementations in pregnancy
      • Wound management and nutrition
      • Gluten free prescribing
    • Palliative Care
    • 10.0 Musculoskeletal and Joint Diseases
      • 10.1 Drugs use in rheumatic diseases and gout
        • 10.1.1. NSAIDs
        • 10.1.2 Corticosteroids
          • 10.1.2.1 Systemic corticosteroids
          • 10.1.2.2 Local corticosteroid injections
        • 10.1.3 Drugs that suppress the rheumatic disease process
        • 10.1.4 Gout and cytotoxic-induced hyperuricaemia
          • 10.1.4.1 Acute attacks of gout
          • 10.1.4.2 Prophylaxis of gout
        • 10.1.5 Other drugs for rheumatic diseases
      • 10.2 Drugs used in neuromuscular disorders
        • 10.2.1 Drugs that enhance neuromuscular transmission
        • 10.2.2 Skeletal muscle relaxants
      • 10.3 Drugs used for the treatment of soft-tissue disorders and topical pain relief
        • 10.3.2 Rubefacients, topical NSAIDs, capsaicin, and poultices
    • 11.0 Eye
      • 11.6 Glaucoma
      • 11.8.1 Dry eye
    • 12.0 Ear, Nose and Oropharynx
    • 13.0 Skin
      • 13.1 Management of skin conditions
      • 13.2 Emollients and barrier preparations
        • 13.2.1 Emollients
          • 13.2.1.1 Emollient bath and shower preparations
        • 13.2.2 Barrier preparations
      • 13.3. Topical local anaesthetics and antipruretics
      • 13.4 Topical corticosteroids
        • 13.4.1 Topical corticosteroids with antimicrobials
      • 13.5 Preparations for eczema and psoriasis
        • 13.5.1 Preparations for eczema
        • 13.5.2. Preparations for psoriasis
          • 13.5.2.1 Trunk and Limbs
          • 13.5.2.1 Scalp
          • 13.5.2.1 Face or Flexures
      • 13.6 Acne and rosacea
        • 13.6.1. Topical preparations for acne
        • 13.6.2 Oral preparations for acne
        • 13.6.3 Rosacea
      • 13.7 Preparations for warts and calluses
      • 13.8 Sunscreens and camouflagers
        • 13.8.1. Sunscreen preparations
          • 13.8.1.1 Photodamage (actinic keratosis)
          • Field Changes
        • 13.8.2 Camouflagers
      • 13.9 Shampoos and other preparations for scalp and hair conditions
      • 13.10 Anti-infective skin preparations
        • 13.10.1.1. Antibacterial preparations only used topically
        • 13.10.1.2. Antibacterial preparations also used systemically
        • 13.10.2 Antifungal preparations
        • 13.10.3 Antiviral preparations
        • 13.10.4 Parasiticidal preparations
      • 13.11 Skin cleansers, antiseptics, and desloughing agents
        • 13.11.1 Alcohols and saline
        • 13.11.2 Chlorhexidine salts
        • 13.11.4. Iodine
        • 13.11.6 Oxidisers and dyes
      • 13.12 Antiperspirants
    • 14.0 Anaesthesia
    • Wound Care Formulary
  • Newsletters & Publications
    • Medicines Management Newsletters
      • Volume 12- 2021
      • Volume 11 – 2020
      • Volume 10 – 2019
      • Volume 9 – 2018
      • Volume 8 – 2017
      • Volume 7 – 2016
      • Volume 6 – 2015
      • Volume 5 – 2014
      • Volume 4 – 2013
      • Volume 3 – 2012
      • Supplements
    • Pharmacy Regional News – ‘PRN’
      • 2022
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
    • Cost Effective Choices and Switching PILs
    • Generic Prescribing Newsletters and Exception List
    • Medicines Safety Matters Newsletters
    • Specials
    • Swallowing Difficulties & Thickening Agents
    • Travel Vaccine Advice
    • Document Library
  • Managed Entry
    • Managed Entry Decisions
    • NICE Clinical Guidelines
    • Biosimilars
  • Deprescribing & OTC
    • OTC
      • Hayfever
      • Painkillers
    • Prescribing Stop List
    • Deprescribing and Polypharmacy Guides
    • Anticholinergic Burden
    • Bisphosphonate Review
  • Patient Zone
    • Epilepsy – lamotrigine information
    • Ordering your Prescription
      • Allow extra time when ordering your prescription
      • Only order what you need!
    • Self Care
      • Go Ahead – treat yourself!
      • Have you had your annual medication review?
      • Managing Ailments without Antibiotics
      • Your Child’s Medicines
      • Your Medicines – Effective Partnership in Care
      • Your Medicines, Your Responsibility
    • Northern Ireland Formulary-the right medicine for you
    • Asthma and COPD
      • Asthma Action Plan
      • Asthma Control Test
      • Am I using my inhaler correctly?
        • Accuhaler
        • Aerolizer
        • Autohaler
        • Breezehaler
        • Clickhaler
        • Easibreathe
        • Easyhaler
        • Ellipta
        • Fospiro
        • Genuair
        • Metered Dose Inhaler
        • Metered Dose Inhaler with Large Volume Spacer
        • Metered Dose Inhaler with Small Volume Spacer
        • NEXThaler
        • Novolizer
        • Respimat
        • Spiriva Handihaler
        • Spiromax
        • Turbohaler
    • Child Health-managing common ailments
      • Administration of Lansoprazole Orodispersible
      • Administration of Omeprazole
    • Coughs, Colds and Sore Throat
      • Common cold
      • Cough and Acute Bronchitis
      • Respiratory Tract Infection (RTI)
      • Sore Ear (Otitis media)
      • Sore Throat
      • Do I need an antibiotic?
      • Does my child need an antibiotic?
    • Diabetes-‘hypos’
    • Epilepsy-levetiracetam information
    • Eye Care
      • Dry Eyes
      • Treatment of Blepharitis
    • Generics
    • Mental Health (including sleep and relaxation)
      • Benzodiazepines and Z Drugs
      • Good Relaxation Guide
      • Good Sleep Guide
      • Recovery Colleges
      • Choice and Medication Website
    • Nutrition
      • Coeliac Disease
      • Cow’s Milk Allergy in Infants
      • Management of Babies with Colic
      • Vitamins
    • Osteoporosis
      • Bisphosphonate Drug Holiday
      • Useful links from Royal Osteoporosis Society
    • Pain
      • Opioid Medicines and the Risk of Addiction
      • Understanding Pain
      • Managing Your Pain Effectively Using “Over the Counter” Medicines
      • Medication for Pain – Patient Information Leaflets
      • Persistent Pain
      • The Pain Toolkit
      • Set Back Plan
      • Codeine Taper Plan
    • Patient Decision Aids
    • Stoma Appliances and Accessories
    • Travel Advice
    • Useful links
  • About & Contact
    • Development and Review of the Formulary
    • Prescribing Guidance Editorial Group Meeting Dates
    • Prescribing Guidance Editorial Group Meeting Minutes
    • Contact Us
Skip to content
  • Home
  • Formulary
    • Chapter Summaries
    • 1.0 Gastro intestinal System
      • 1.1 Dyspepsia and gastro-oesophageal reflux disease (GORD)
        • 1.1.1 Antacids and simeticone
        • 1.1.2 Compound alginates and proprietary indigestion preparations
      • 1.2 Antispasmodics and other drugs altering gut motility
      • 1.3 Antisecretory drugs and mucosal protectants
        • 1.3.1 H2-receptor antagonists
        • 1.3.5 Proton pump inhibitors
          • 1.3.5.1 H.pylori eradication
      • 1.4 Acute diarrhoea
      • 1.5 Chronic bowel disorders
        • 1.5.1 Aminosalicylates
          • 1.5.1.1 Acute Exacerbation of ulcerative colitis
          • 1.5.1.2 Maintenance of remission of ulcerative colitis
        • 1.5.2 Corticosteroids inflammatory bowel disease
        • 1.5.3 Steroid-sparing treatment for inflammatory bowel disease
      • 1.6 Laxatives
      • 1.7 Local preparations for anal and rectal disorders
        • 1.7.1 Soothing haemorrhoidal preparations
        • 1.7.2 Compound haemorrhoidal preparations with corticosteroids
        • 1.7.4 Management of anal fissures
      • 1.9 Drugs affecting intestinal secretions
        • 1.9.4 Pancreatic Exocrine Insufficiency
    • 2.0 Cardiovascular System
      • 2.1 Positive inotropic drugs
        • 2.1.1 Cardiac glycosides
      • 2.2 Diuretics
        • 2.2.1 Thiazides and related diuretics
        • 2.2.2 Loop diuretics
        • 2.2.3 Potassium-sparing diuretics and aldosterone antagonists
        • 2.2.4 Potassium-sparing diuretics with other diuretics
      • 2.3 Anti-arrhythmic drugs
        • 2.3.2 Drugs for arrhythmias
      • 2.4 Beta-adrenoceptor blocking drugs
      • 2.5 Hypertension and heart failure
        • 2.5.2 Centrally acting antihypertensive drugs
        • 2.5.4 Alpha-adrenoceptor blocking drugs
        • 2.5.5 Drugs affecting the renin-angiotensin system
          • 2.5.5.1 Angiotensin-converting enzyme inhibitors
          • 2.5.5.2 Angiotensin-II receptor antagonists (AIIRAs/ARBs)
          • 2.5.5.3 Renin inhibitors
      • 2.6 Nitrates, calcium-channel blockers and other antianginal drugs
        • 2.6.1 Nitrates
        • 2.6.2 Calcium-channel blockers (CCBs)
        • 2.6.3 Other antianginal drugs
        • 2.6.4 Peripheral vasodilators and related drugs
        • Review copy of – 2.6.3 Other antianginal drugs
      • 2.7 Sympathomimetics
      • 2.8 Anticoagulants and protamine
        • 2.8.1 Parenteral anticoagulants
        • 2.8.2 Oral anticoagulants
          • 2.8.2.1 Atrial fibrillation
          • 2.8.2.2 Treatment of pulmonary embolism and deep vein thrombosis and prevention of recurrent
          • 2.8.2.3 Prophylaxis of venous thromboembolism in orthopaedics-specialist use in secondary care only
          • 2.8.2.4 Acute coronary syndrome
          • 2.8.2.5 Prevention of Atherothrombotic events
      • 2.9 Antiplatelet drugs
      • 2.10 Stable angina, acute coronary syndromes and fibrinolysis
      • 2.11 Antifibrinolytic drugs and haemostatics
      • 2.12 Lipid-regulating drugs
    • 3.0 Respiratory System
      • 3.1 Bronchodilators
        • 3.1.1 Adrenoceptor agonists
        • 3.1.2 Antimuscarinic bronchodilators
        • 3.1.3 Theophylline
        • 3.1.4 Compound bronchodilator preparations
        • 3.1.5 Peak flow meters, inhaler devices and nebulisers
      • 3.2 Corticosteroids
        • 3.2.1 Single agent inhalers [asthma only]
        • 3.2.2 Compound ICS/LABA preparations – [asthma]
        • 3.2.3 Compound ICS/LABA preparations – COPD
        • 3.2.4 Systemic steroids
      • 3.3 Leukotriene receptor antagonists and phosphodiesterase type-4 inhibitors
        • 3.3.2 Leukotriene receptor antagonists
        • 3.3.3 Phosphodiesterase type-4 inhibitors
      • 3.4 Antihistamines, hyposensitisation and allergic emergencies
        • 3.4.1 Antihistamines
        • 3.4.2 Allergen immunotherapy (desensitisation)
        • 3.4.3 Allergic emergencies
      • 3.6 Oxygen
      • 3.7 Mucolytics
      • 3.9 Cough preparations
        • 3.9.1 Cough suppressants
    • 4.0 Central Nervous System
      • 4.1 Hypnotics and anxiolytics
        • 4.1.1 Hypnotics
        • 4.1.2 Anxiolytics
          • 4.1.2.1 Acute anxiety state
          • 4.1.2.2 Anxiety disorders
        • 4.1.3 Barbiturates
      • 4.2 Drugs used in psychoses and related disorders
        • 4.2.1 Antipsychotic drugs
          • 4.2.1.1 Management of agitation and aggression
        • 4.2.3 Mood stabilising drugs
          • 4.2.3.1 Treatment of the acute phase of mania
          • 4.2.3.2 Maintenance treatment of bipolar disorder with mood stabilisers
      • 4.3 Antidepressant drugs
        • 4.3.1 Mild, moderate and severe depression
        • 4.3.2 Antidepressants for the treatment of anxiety disorders*
          • 4.3.2.1 Generalised anxiety disorder (GAD), social anxiety disorder
          • 4.3.2.2 Panic disorder
          • 4.3.2.3 Post-traumatic stress disorder
          • 4.3.2.4 Obsessive compulsive disorder
      • 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder
        • 4.4.1 Narcolepsy
        • 4.4.2 Attention deficit hyperactive disorder (ADHD) in adults
      • 4.5 Drugs used in the treatment of obesity
        • 4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract
      • 4.6 Drugs used in nausea and vertigo
        • 4.6.1 Drugs for the short-term treatment of nausea and vomiting
          • 4.6.1.1 Motion sickness
        • 4.6.2 Vertigo
      • 4.7 Analgesics
        • 4.7.1 General management of acute pain
          • 4.7.1.1 Non-opioid & compound analgesics
          • 4.7.1.2 Opioid analgesics
        • 4.7.3 Neuropathic pain
        • 4.7.4 Antimigraine drugs
          • 4.7.4.1 Treatment of acute migraine attack
          • 4.7.4.2 Migraine prophylaxis
          • 4.7.4.3 Drug treatment of cluster headache
      • 4.8 Anti-epileptics
        • 4.8.1 Control of epilepsy
        • 4.8.2 Drugs used in status epilepticus
      • 4.9 Drugs used in parkinsonism and related disorders
        • 4.9.1 Dopaminergic drugs used in parkinsonism
          • 4.9.1.1 Dopamine receptor agonists
          • 4.9.1.2 Levodopa
          • 4.9.1.3 Monoamine-oxidase-B (MAOB) inhibitors
          • 4.9.1.4 Dopamine enzyme inhibitors / catechol-O-methyltransferase inhibitors (COMT inhibitors)
        • 4.9.2 Antimuscarinic drugs used in parkinsonism
        • 4.9.3 Essential tremor
        • 4.9.4 Management of dementia in Parkinson’s disease
      • 4.10 Medications used in substance use disorders
        • 4.10.1 Opioid maintenance prescribing
        • 4.10.2 Opioid detoxification
        • 4.10.3 Benzodiazepines addiction and withdrawal
        • 4.10.4 Alcohol dependence
          • 4.10.4.1 Acute alcohol withdrawal
          • 4.10.4.2 Relapse Prevention
          • 4.10.4.3 Interventions for the reduction of alcohol consumption
          • 4.10.4.4 Vitamin supplementation
        • 4.10.5 Cigarette smoking
      • 4.11 Drugs for dementia
        • 4.11.1 Management of Behavioural and Psychological Symptoms of Dementia (BPSD)
    • 5.0 Infections (including children)
    • 6.0 Endocrine
      • 6.1 Drugs used in diabetes
        • 6.1.1 Insulins
        • 6.1.2 Antidiabetic drugs
          • 6.1.2.1 Biguanides
          • 6.1.2.2 Sulfonlyureas
          • 6.1.2.3 Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors)
          • 6.1.2.4 Glitazones (thiazolidinediones)
          • 6.1.2.5 Sodium-glucose co-transporter 2 (SGLT-2) inhibitors
          • 6.1.2.6 GLP-1 mimetic (injectable)
          • Sick Day rules
        • 6.1.4 Treatment of hypoglycaemia
        • 6.1.6 Diagnostic and monitoring agents for diabetes mellitus
        • Summary of oral drug treatments for type 2 diabetes
      • 6.2 Thyroid and antithyroid drugs and parathyroid disease
        • 6.2.1 Hypothyroidism
        • 6.2.2 Hyperthyroidism
          • 6.2.2.1 Antithyroid drugs
          • 6.2.2.2 Beta-blockers
        • 6.2.3 Parathyroid disease
          • 6.2.3.1 Hyperparathyroidism
          • 6.2.3.2 Hypoparathyroidism
      • 6.3 Corticosteroids
        • 6.3.1 Replacement therapy
        • 6.3.2 Glucocorticoid therapy
      • 6.4 Sex hormones
        • 6.4.1.1 Hormone replacement therapy (HRT) for menopausal symptoms
          • 6.4.1.1a Women who have not had a hysterectomy
          • 6.4.1.1b Women who have had a hysterectomy or who have a Mirena® Intra Uterine System (ISU) in situ
        • 6.4.2 Male sex hormones
      • 6.5 Pituitary hormones and anti-oestrogens
        • 6.5.2 Posterior pituitary hormones and antagonists
          • 6.5.2.1 Diabetes insipidus
          • 6.5.2.2 Antidiuretic hormone antagonists
      • 6.6 Drugs affecting bone metabolism
        • 6.6.1 Drugs for the treatment and management of osteoporosis
          • 6.6.1.1 Calcium and vitamin D
          • 6.6.1.2 Bisphosphonates
          • 6.6.1.3 Other drug therapies used in osteoporosis
      • 6.7 Other endocrine drugs
        • 6.7.1 Dopamine-receptor agonists
        • 6.7.4 Growth hormone disorders
    • 7.0 Contraception, Gynaecology and Urinary Tract Disorders
      • 7.1.1 Primary dysmenorrhoea
      • 7.1.2 Heavy menstrual bleeding
      • 7.1.3 Endometriosis (previously diagnosed by laparoscopy)
      • 7.1.4 Lichen sclerosus
      • 7.1.5 Persistent breast pain
      • 7.1.6 Premenstrual tension syndrome
      • 7.1.7 Polycystic ovarian syndrome
      • 7.2 Treatment of vaginal and vulval conditions
        • 7.2.1 Preparations for vaginal and vulval changes
        • 7.2.2 Vaginal and vulval infections
      • 7.3 Contraceptives
        • 7.3.1 Combined hormonal oral contraceptives
        • 7.3.2 Progestogen-only contraceptives
          • 7.3.2.1 Oral progestogen-only contraceptives
          • 7.3.2.2 Parenteral progestogen-only contraceptives
          • 7.3.2.3. Intra-uterine progestogen-only device
        • 7.3.4 Contraceptive devices
        • 7.3.5 Emergency contraception
        • 7.3.6 Delaying Menstruation During Holidays
      • 7.4 Drugs for genito-urinary disorders
        • 7.4.1 Drugs for voiding (obstructive) symptoms in men
        • 7.4.2 Drugs for urinary frequency, enuresis, and incontinence
        • 7.4.3 Drugs used in urological pain
        • 7.4.5 Drugs for erectile dysfunction
    • 8.0 Malignant Disease and Immunosuppression
    • 9.0 Nutrition and Blood
      • 9.1 Anaemias and some other blood disorders
        • 9.1.1 Iron deficiency anaemia
          • 9.1.1.1 Oral iron
        • 9.1.2 Drugs used in megaloblastic anaemias
      • 9.4 Oral Nutrition
      • 9.5 Minerals
        • 9.5.1.1 Calcium supplement
      • 9.6 Vitamins
        • 9.6.2 Vitamin B group
        • 9.6.4 Vitamin D
        • 9.6.7 Multivitamins
      • Infant Feeding
      • Supplementations in pregnancy
      • Wound management and nutrition
      • Gluten free prescribing
    • Palliative Care
    • 10.0 Musculoskeletal and Joint Diseases
      • 10.1 Drugs use in rheumatic diseases and gout
        • 10.1.1. NSAIDs
        • 10.1.2 Corticosteroids
          • 10.1.2.1 Systemic corticosteroids
          • 10.1.2.2 Local corticosteroid injections
        • 10.1.3 Drugs that suppress the rheumatic disease process
        • 10.1.4 Gout and cytotoxic-induced hyperuricaemia
          • 10.1.4.1 Acute attacks of gout
          • 10.1.4.2 Prophylaxis of gout
        • 10.1.5 Other drugs for rheumatic diseases
      • 10.2 Drugs used in neuromuscular disorders
        • 10.2.1 Drugs that enhance neuromuscular transmission
        • 10.2.2 Skeletal muscle relaxants
      • 10.3 Drugs used for the treatment of soft-tissue disorders and topical pain relief
        • 10.3.2 Rubefacients, topical NSAIDs, capsaicin, and poultices
    • 11.0 Eye
      • 11.6 Glaucoma
      • 11.8.1 Dry eye
    • 12.0 Ear, Nose and Oropharynx
    • 13.0 Skin
      • 13.1 Management of skin conditions
      • 13.2 Emollients and barrier preparations
        • 13.2.1 Emollients
          • 13.2.1.1 Emollient bath and shower preparations
        • 13.2.2 Barrier preparations
      • 13.3. Topical local anaesthetics and antipruretics
      • 13.4 Topical corticosteroids
        • 13.4.1 Topical corticosteroids with antimicrobials
      • 13.5 Preparations for eczema and psoriasis
        • 13.5.1 Preparations for eczema
        • 13.5.2. Preparations for psoriasis
          • 13.5.2.1 Trunk and Limbs
          • 13.5.2.1 Scalp
          • 13.5.2.1 Face or Flexures
      • 13.6 Acne and rosacea
        • 13.6.1. Topical preparations for acne
        • 13.6.2 Oral preparations for acne
        • 13.6.3 Rosacea
      • 13.7 Preparations for warts and calluses
      • 13.8 Sunscreens and camouflagers
        • 13.8.1. Sunscreen preparations
          • 13.8.1.1 Photodamage (actinic keratosis)
          • Field Changes
        • 13.8.2 Camouflagers
      • 13.9 Shampoos and other preparations for scalp and hair conditions
      • 13.10 Anti-infective skin preparations
        • 13.10.1.1. Antibacterial preparations only used topically
        • 13.10.1.2. Antibacterial preparations also used systemically
        • 13.10.2 Antifungal preparations
        • 13.10.3 Antiviral preparations
        • 13.10.4 Parasiticidal preparations
      • 13.11 Skin cleansers, antiseptics, and desloughing agents
        • 13.11.1 Alcohols and saline
        • 13.11.2 Chlorhexidine salts
        • 13.11.4. Iodine
        • 13.11.6 Oxidisers and dyes
      • 13.12 Antiperspirants
    • 14.0 Anaesthesia
    • Wound Care Formulary
  • Newsletters & Publications
    • Medicines Management Newsletters
      • Volume 12- 2021
      • Volume 11 – 2020
      • Volume 10 – 2019
      • Volume 9 – 2018
      • Volume 8 – 2017
      • Volume 7 – 2016
      • Volume 6 – 2015
      • Volume 5 – 2014
      • Volume 4 – 2013
      • Volume 3 – 2012
      • Supplements
    • Pharmacy Regional News – ‘PRN’
      • 2022
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
    • Cost Effective Choices and Switching PILs
    • Generic Prescribing Newsletters and Exception List
    • Medicines Safety Matters Newsletters
    • Specials
    • Swallowing Difficulties & Thickening Agents
    • Travel Vaccine Advice
    • Document Library
  • Managed Entry
    • Managed Entry Decisions
    • NICE Clinical Guidelines
    • Biosimilars
  • Deprescribing & OTC
    • OTC
      • Hayfever
      • Painkillers
    • Prescribing Stop List
    • Deprescribing and Polypharmacy Guides
    • Anticholinergic Burden
    • Bisphosphonate Review
  • Patient Zone
    • Epilepsy – lamotrigine information
    • Ordering your Prescription
      • Allow extra time when ordering your prescription
      • Only order what you need!
    • Self Care
      • Go Ahead – treat yourself!
      • Have you had your annual medication review?
      • Managing Ailments without Antibiotics
      • Your Child’s Medicines
      • Your Medicines – Effective Partnership in Care
      • Your Medicines, Your Responsibility
    • Northern Ireland Formulary-the right medicine for you
    • Asthma and COPD
      • Asthma Action Plan
      • Asthma Control Test
      • Am I using my inhaler correctly?
        • Accuhaler
        • Aerolizer
        • Autohaler
        • Breezehaler
        • Clickhaler
        • Easibreathe
        • Easyhaler
        • Ellipta
        • Fospiro
        • Genuair
        • Metered Dose Inhaler
        • Metered Dose Inhaler with Large Volume Spacer
        • Metered Dose Inhaler with Small Volume Spacer
        • NEXThaler
        • Novolizer
        • Respimat
        • Spiriva Handihaler
        • Spiromax
        • Turbohaler
    • Child Health-managing common ailments
      • Administration of Lansoprazole Orodispersible
      • Administration of Omeprazole
    • Coughs, Colds and Sore Throat
      • Common cold
      • Cough and Acute Bronchitis
      • Respiratory Tract Infection (RTI)
      • Sore Ear (Otitis media)
      • Sore Throat
      • Do I need an antibiotic?
      • Does my child need an antibiotic?
    • Diabetes-‘hypos’
    • Epilepsy-levetiracetam information
    • Eye Care
      • Dry Eyes
      • Treatment of Blepharitis
    • Generics
    • Mental Health (including sleep and relaxation)
      • Benzodiazepines and Z Drugs
      • Good Relaxation Guide
      • Good Sleep Guide
      • Recovery Colleges
      • Choice and Medication Website
    • Nutrition
      • Coeliac Disease
      • Cow’s Milk Allergy in Infants
      • Management of Babies with Colic
      • Vitamins
    • Osteoporosis
      • Bisphosphonate Drug Holiday
      • Useful links from Royal Osteoporosis Society
    • Pain
      • Opioid Medicines and the Risk of Addiction
      • Understanding Pain
      • Managing Your Pain Effectively Using “Over the Counter” Medicines
      • Medication for Pain – Patient Information Leaflets
      • Persistent Pain
      • The Pain Toolkit
      • Set Back Plan
      • Codeine Taper Plan
    • Patient Decision Aids
    • Stoma Appliances and Accessories
    • Travel Advice
    • Useful links
  • About & Contact
    • Development and Review of the Formulary
    • Prescribing Guidance Editorial Group Meeting Dates
    • Prescribing Guidance Editorial Group Meeting Minutes
    • Contact Us
Home Formulary 7.0 Contraception, Gynaecology and Urinary Tract Disorders 7.1.5 Persistent breast pain

Quick Links

Contents

  • 7.1.1 Primary dysmenorrhoea
  • 7.1.2 Heavy menstrual bleeding
  • 7.1.3 Endometriosis (previously diagnosed by laparoscopy)
  • 7.1.4 Lichen sclerosus
  • 7.1.5 Persistent breast pain
  • 7.1.6 Premenstrual tension syndrome
  • 7.1.7 Polycystic ovarian syndrome
  • 7.2 Treatment of vaginal and vulval conditions
    • 7.2.1 Preparations for vaginal and vulval changes
    • 7.2.2 Vaginal and vulval infections
  • 7.3 Contraceptives
    • 7.3.1 Combined hormonal oral contraceptives
    • 7.3.2 Progestogen-only contraceptives
      • 7.3.2.1 Oral progestogen-only contraceptives
      • 7.3.2.2 Parenteral progestogen-only contraceptives
      • 7.3.2.3. Intra-uterine progestogen-only device
    • 7.3.4 Contraceptive devices
    • 7.3.5 Emergency contraception
    • 7.3.6 Delaying Menstruation During Holidays
  • 7.4 Drugs for genito-urinary disorders
    • 7.4.1 Drugs for voiding (obstructive) symptoms in men
    • 7.4.2 Drugs for urinary frequency, enuresis, and incontinence
    • 7.4.3 Drugs used in urological pain
    • 7.4.5 Drugs for erectile dysfunction

7.1.5 Persistent breast pain

Refer to CKS guidance on cyclical breast pain.

 

Useful Links
  • Disclaimer
  • Privacy Policy
  • Contact Us